Advertisement

Directions for Research in the Post-Myocardial Infarction Patient with Left Ventricular Dysfunction

      Left ventricular dysfunction (LVD) in post-myocardial infarction (MI) patients is an important predictor of a poor prognosis. LVD may be asymptomatic in the post-MI patient, but it can also manifest as heart failure (HF) or sudden cardiac death. Early revascularization and pharmacologic therapy targeting coronary artery disease (CAD) and LVD reduce post-MI mortality as well as rates of HF and recurrent MI. However, despite dramatic gains in the treatment of post-MI LVD, there remains considerable room for improvement. The following is a brief summary of important areas of investigation addressing this goal.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fonarow G.C.
        • Yancy C.W.
        • Heywood J.T.
        Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry.
        Arch Intern Med. 2005; 165: 1469-1477
        • Fonarow G.C.
        • Abraham W.T.
        • Albert N.M.
        • Gattis W.A.
        • Gheorghiade M.
        • Greenberg B.H.
        • O'Connor C.M.
        • Pieper K.
        • Sun J.L.
        • Yancy C.W.
        • Young J.
        Association between performance measures and clinical outcomes for patients hospitalized with heart failure.
        JAMA. 2007; 297: 61-70
        • Felker G.M.
        • Benza R.L.
        • Chandler A.B.
        • Leimberger J.D.
        • Cuffe M.S.
        • Califf R.M.
        • Gheorghiade M.
        • O'Connor C.M.
        Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
        J Am Coll Cardiol. 2003; 41: 997-1003
        • Roccaforte R.
        • Demers C.
        • Baldasarre F.
        • Teo K.K.
        • Yusuf S.
        Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients: a meta-analysis.
        Eur J Heart Fail. 2005; 7: 1133-1144
        • Jourdain P.
        • Jondeau G.
        • Funck F.
        • Gueffet P.
        • Le Helloco A.
        • Donal E.
        • Aupetit J.F.
        • Aumont M.C.
        • Galinier M.
        • Eicher J.C.
        • Cohen-Solal A.
        • Juillière Y.
        Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study.
        J Am Coll Cardiol. 2007; 49: 1733-1739
        • Stanton A.
        • Jensen C.
        • Nussberger J.
        • O'Brien E.
        Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
        Hypertension. 2003; 42: 1137-1143
        • Gradman A.H.
        • Schmieder R.E.
        • Lins R.L.
        • Nussberger J.
        • Chiang Y.
        • Bedigian M.P.
        Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
        Circulation. 2005; 111: 1012-1018
        • Cleland J.G.
        • Abdellah A.T.
        • Khaleva O.
        • Coletta A.P.
        • Clark A.L.
        Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
        Eur J Heart Fail. 2007; 9: 1070-1073
        • Münzel T.
        • Genth-Zotz S.
        • Hink U.
        Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure?.
        Hypertension. 2007; 49: 974-976
        • Boerrigter G.
        • Costello-Boerrigter L.C.
        • Cataliotti A.
        • Lapp H.
        • Stasch J.P.
        • Burnett Jr, J.C.
        Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
        Hypertension. 2007; 49: 1128-1133
        • Cleland J.G.F.
        • Coletta A.P.
        • Clark A.L.
        Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF.
        Eur J Heart Fail. 2006; 8: 764-766
        • Hall J.L.
        • Birks E.J.
        • Grindle S.
        • Cullen M.E.
        • Barton P.J.
        • Rider J.E.
        • Lee S.
        • Harwalker S.
        • Mariash A.
        • Adhikari N.
        • et al.
        Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy.
        Eur Heart J. 2007; 28: 613-627
        • Barton P.J.R.
        • Felkin L.E.
        • Birks E.J.
        • Cullen M.E.
        • Banner N.R.
        • Grindle S.
        • Hall J.L.
        • Miller L.W.
        • Yacoub M.H.
        Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.
        Circulation. 2005; 112: I-46-I-50
        • Di Francesco D.
        • Camm A.J.
        Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
        Drugs. 2004; 64: 1757-1765
        • Fox K.
        • Ferrari R.
        • Tendera M.
        • Steg P.G.
        • Ford I.
        Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
        Am Heart J. 2006; 152: 860-866
        • Smart N.
        • Risebro C.A.
        • Melville A.A.
        • Moses K.
        • Schwartz R.J.
        • Chien K.R.
        • Riley P.R.
        Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.
        Nature. 2007; 445: 177-182
        • Weintraub A.J.
        • Kimmelstiel C.
        • Levine D.
        • Venesy D.
        • Levin A.
        • Lorell B.
        • Patel A.
        • Gregory D.
        • Delano C.
        • Perry K.
        • Konstam V.
        • Konstam M.A.
        A multicenter, randomized, controlled comparison of telephonic disease management vs automated home monitoring in patients recently hospitalized with heart failure: SPAN-CHF II trial.
        Program and abstracts from the 9th Annual Scientific Meeting of the Heart Failure Society of America, Boca Raton, Fla2005 (September 18-21)
        • Cleland J.G.F.
        • Louis A.A.
        • Rigby A.S.
        • Janssens U.
        • Balk A.H.
        Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home–Care Management System (TEN-HMS) study.
        J Am Coll Cardiol. 2005; 45: 1654-1664
        • Goldberg L.R.
        • Piette J.D.
        • Walsh M.N.
        • Frank T.A.
        • Jaski B.E.
        • Smith A.L.
        • Rodriguez R.
        • Mancini D.M.
        • Hopton L.A.
        • Orav E.J.
        • Loh E.
        Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial.
        Am Heart J. 2003; 146: 705-712
        • Whellan D.J.
        • O'Connor C.M.
        • Lee K.L.
        • Keteyian S.J.
        • Cooper L.S.
        • Ellis S.J.
        • Leifer E.S.
        • Kraus W.E.
        • Kitzman D.W.
        • Blumenthal J.A.
        • et al.
        Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION): design and rationale.
        Am Heart J. 2007; 153: 201-211
        • Erne P.
        • Schoenenberger A.W.
        • Burckhardt D.
        • Zuber M.
        • Kiowski W.
        • Buser P.T.
        • Dubach P.
        • Resink T.J.
        • Pfisterer M.
        Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial.
        JAMA. 2007; 297: 1985-1991
        • Allman K.C.
        • Shaw L.J.
        • Hachamovitch R.
        • Udelson J.E.
        Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.
        J Am Coll Cardiol. 2002; 39: 1151-1158
        • Cleland J.G.F.
        • Freemantle N.
        • Ball S.G.
        • Bonser R.S.
        • Camici P.
        • Chattopadhyay S.
        • Dutka D.
        • Eastaugh J.
        • Hampton J.
        • Large S.
        • et al.
        The heart failure revascularisation trial (HEART): rationale, design and methodology.
        Eur J Heart Fail. 2003; 5: 295-303
        • Moss A.J.
        • Hall W.J.
        • Cannom D.S.
        • Daubert J.P.
        • Higgins S.L.
        • Klein H.
        • Levine J.H.
        • Saksena S.
        • Waldo A.L.
        • Wilber D.
        • Brown M.W.
        • Heo M.
        Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia.
        N Engl J Med. 1996; 335: 1933-1940
        • Moss A.J.
        • Zareba W.
        • Hall W.J.
        • Klein H.
        • Wilber D.J.
        • Cannom D.S.
        • Daubert J.P.
        • Higgins S.L.
        • Brown M.W.
        • Andrews M.L.
        Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
        N Engl J Med. 2002; 346: 877-883
        • Bristow M.R.
        • Saxon L.A.
        • Boehmer J.
        • Krueger S.
        • Kass D.A.
        • De Marco T.
        • Carson P.
        • DiCarlo L.
        • DeMets D.
        • White B.G.
        • DeVries D.W.
        • Feldman A.M.
        Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
        N Engl J Med. 2004; 350: 2140-2150
        • Moss A.J.
        • Brown M.W.
        • Cannom D.S.
        • Daubert J.P.
        • Estes M.
        • Foster E.
        • Greenberg H.M.
        • Hall W.J.
        • Higgins S.L.
        • Klein H.
        • et al.
        Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT): design and clinical protocol.
        Ann Noninvasive Electrocardiol. 2005; 10: 34-43
        • Ripa R.S.
        • Jørgensen E.
        • Wang Y.
        • Thune J.J.
        • Nilsson J.C.
        • Søndergaard L.
        • Johnsen H.E.
        • Køber L.
        • Grande P.
        • Kastrup J.
        Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial.
        Circulation. 2006; 113: 1983-1992
        • Ince H.
        • Petzsch M.
        • Kleine H.D.
        • Eckard H.
        • Rehders T.
        • Burska D.
        • Kische S.
        • Freund M.
        • Nienaber C.A.
        Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) trial.
        Circulation. 2005; 112: I-73-I-80
        • Kang H.J.
        • Kim H.S.
        • Zhang S.Y.
        • Park K.W.
        • Cho H.J.
        • Koo B.K.
        • Kim Y.J.
        • Soo Lee D.
        • Sohn D.W.
        • Han K.S.
        • et al.
        Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial.
        Lancet. 2004; 363: 751-756
        • Losordo D.W.
        • Schatz R.A.
        • White C.J.
        • Udelson J.E.
        • Veereshwarayya V.
        • Durgin M.
        • Poh K.K.
        • Weinstein R.
        • Kearney M.
        • Chaudhry M.
        • et al.
        Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
        Circulation. 2007; 115: 3165-3172
        • Assmus B.
        • Fischer-Rasokat U.
        • Honold J.
        • Seeger F.
        • Fichtlscherer S.
        • Tonn T.
        • Schaechinger V.
        • Dimmeler S.
        • Zeiher A.
        Transcoronary transplantation of functionally competent bone marrow cells is associated with decreased natriuretic peptide levels and improved survival in post-infarction heart failure patients [abstract].
        Eur Heart J. 2007; 28: 297
        • Nyolczas N.
        • Gyöngyösi M.
        • Beran G.
        • Dettke M.
        • Graf S.
        • Sochor H.
        • Christ G.
        • Édes I.
        • Balogh L.
        • Krause K.T.
        • et al.
        Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
        Am Heart J. 2007; 153: 212.e1-212.e7
        • Abraham W.T.
        • Greenberg B.H.
        • Yancy C.W.
        Pharmacologic therapies across the continuum of left ventricular function.
        Am J Cardiol. 2008; 102: 21G-28G
        • Kadish A.H.
        • Reiffel J.A.
        • Naccarelli G.V.
        • DiMarco J.P.
        Device therapies in the post–myocardial infarction patient with left ventricular dysfunction.
        Am J Cardiol. 2008; 102: 29G-37G
        • Flaherty J.D.
        • Davidson C.J.
        • Faxon D.P.
        Percutaneous coronary intervention for myocardial infarction with left ventricular dysfunction.
        Am J Cardiol. 2008; 102: 38G-41G
        • McCarthy P.M.
        Surgical therapies for post–myocardial infarction patients.
        Am J Cardiol. 2008; 102: 42G-46G